We developed a method for measuring pentobarbital in samples that also contain phenobarbital. The phenobarbital is destroyed by adding sodium hydroxide and then heating at 95#{176}C for 60 mm. Pentobarbital is not affected by this pretreatment and can then be measured with an Abbott TDx barbiturates kit. Using this method, we obtained an average analytical recovery of 98% of added pentobarbital and a correlation of y = O.953x + 3.4 vs HPLC. The intra-assay CV was 3.7% at 25.8 mg/L; the interassay CV was 6.2% at 16.1 mg/L Other long-acting barbiturates, e.g., hexobarbital, are also effectively destroyed by this alkali pretreatment. Other short-acting barbiturates, e.g., secobarbital, are not removed and would produce an interference.
from patients who have also received phenobarbital, we extended the application of these automated immunoassay procedures to mixed barbiturate samples by adding a sample pretreatment step.
In 1955, Broughton (18) reported that the differential stability of the barbiturates to basic hydrolysis could be combined with ultraviolet spectroscopy to partially identify the barbiturates. The short-acting barbiturates such as pentobarbital are relatively resistant to hydrolysis, whereas the long-acting barbiturates such as phenobarbital are highly susceptible to hydrolysis. We combined this basic hydrolysis with immunoassay in the TDx to produce a method for measuring pentobarbital in the presence of phenobarbital.
MaterIals and Methods

lmmunoassay
We quantified pentobarbital with an Abbott TDx, using the Barbiturates reagent pack (Abbott Diagnostic Division, Abbott Park, IL 60064). Calibrators were prepared by adding pentobarbital to drug-free serum (Bio-Rad Labs., Hercules, CA 94547) to produce concentrations of 2.5, 5.0, 10.0, and 50 mg/L. Aliquota of the calibrators were frozen at -20 #{176}C until use. We manually diluted standards, controls, and patients' samples 21-fold with TDx buffer (0.1 mol/L phosphate buffer, pH 7.6; Abbott cat. no. 9519) and then analyzed them according to the manufacturer's usual protocol. Calibrators were run in duplicate, controls and patients' samples as singletons. We determined the presence of phenobarbital in patients' samples by analysis with the TDx and the Phenobarbital II kit (Abbott Diagnostic Division). Specimens with phenobarbital concentrations >1.0 mg/L were treated with base and heated to destroy the phenobarbital before measurement of pentobarbital, as follows: 50 pL of the serum was mixed with 50 pL of lmoliLNaOHinalO x 75 mmglasstesttube and heated for 1 h at 95#{176}C in a Reacti-Therm Heating Module (Pierce Chemical Co., Rockforcl, IL 61105). We neutralized the NaOH with 50 ML of 1 mol/L HC1, then diluted the mixture with 900 ,uL of TDx buffer. The diluted specimens were then loaded onto a TDx carousel and analyzed by using the Barbiturates kit.
HPLC
We performed the chromatographic determinations at ambient temperature with a Waters 600E liquid chromatograph, using a 30 cm x 4 mm pBondapak C15 column packed with 10-tim particles and a Model 484 variable-wavelength ultraviolet detector at 214 nm (Waters Chromatography Division,Milford, MA 01757).
Penteberbftal, mg/I. The mobile phase consisted of acetomtrile and 1 g/L trimethyl ammonium phosphate buffer, pH 3.0 (35/65 by vol) and the flow rate was 1.5 mL/min. Secobarbital, 25 mg/L, was used as the internal standard. Standards were prepared by adding pentobarbital and phenobarbital to drug-free serum to final concentrations of 25 and 100 mg/L, respectively. We prewashed 100 mg (1.0-mL) C18 Bond-Elut columns (Analytichem International, Harbor City, CA 90710) with two 1.0-mL aliquots of methanol followed by two 1.0-mL aliquots of water. We then applied 100 MLof standard, control, or patient's sample to a column and added 100 ML of the internal standard. After rinsing the column three times with 1.0-mL aliquots of water, we eluted the drugs with 250 ILL of methanol. A 25-pL aliquot of the eluate was injected into the chromatograph for analysis.
Added
Resufts
The alkaline digestion effectively removed the phenobarbital; however, a 1-h incubation was required to ensure complete destruction of the higher concentrations of this drug (Figure 1 ). This same treatment did not affect the pentobarbital content.
Comparison of results for 23 patients receiving both pentobarbital and phenobarbital, as determined by immunoassay after alkaline digestion (y) and HPLC (x) gave a regression (28) of y = 0.953x (Table 1 ). The effect of the alkali digestionon other barbiturates was tested by preparing 20 mg/L solutions in drug-free serum and analyzing them by the current procedure. The effective pentobarbital concentrations are given in Table 2 Cross-reactivity with other drugs was evaluated by assaying a multi-drug control material containing parent compounds as well as patients' samples submitted for therapeutic drug monitoring (Table 3) . 30 40
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FIg. 1. TImecourseforthe elimination of phenobarbltal byalkaline hydrolysis
After the addition of sodium hydroxide,the samples were heated for the times shown,thenanalyzedwiththeTDx as described in Materialsand Methods.At bothconcentrations of sodium hydroxide(1 and 2 moUL),phenobathltal was effectively removed after 60 mm, whereas pentobarbftal was unaffected 
DIscussion
The barbiturate kit used for this study was specifically designed to detect a wide variety of barbituratesin urine in drug-abuse situations. Therefore, our serum samples required pre-dilution because of the much higher concentrations seen when these drugs are given therapeutically. When all samples, standards, and controls were diluted 21-fold with TDx buffer and the instrument was calibrated with pentobarbital, the test performance was similar to that in previous reports (26) .
We noted an increase in requests for pentobarbital measurement where the patient had also received phe-nobarbital. This presented a problem because the kit was specifically designed to cross-react with other barbiturates, including phenobarbital.
We originally thought that it might be possible to measure the total barbiturate concentration with this nonspecific kit, measure the phenobarbital concentration with the usual phenobarbital-specific serum kit, and calculate the pentobarbital concentration as the difference. This approach would be possible even if the response of the nonspecific urine barbiturate kit to phenobarbital was not equivalent to that for pentobarbital, as long as a curve of pentobarbital-equivalent response vs actual phenobarbital concentration could be defined. However, as shown in Figure 2 , the responseof the barbiturate kit to phenobarbital after calibration to pentobarbital was not constant; the phenobarbital cross-reactivity increased rapidly from near unity at lower concentrations to several-fold that of pentobarbital at higher concentrations. This would have required calibration of the total barbiturate assay up to a pentobarbital concentration of 200 mg/L to cover even the lower half of the phenobarbital therapeutic range. The subsequent uncertainty in the pentobarbital concentration, calculated as the difference between two large numbers, would have been unacceptable.
The alkaline-digestion method of Broughton (18) appeared to offer a way to remove the phenobarbital before pentobarbital measurement. By extending the hydrolysis step to 60 mm, we destroyed all of the phenobarbital while leaving the pentobarbital intact (Figure 1) . Sodium hydroxide concentrations as great as 2 mol/L did not significantly shorten this time. The imprecision, although slightly greater than for standard TDx drug assays, was reasonably good,considering the extra sample manipulation required. Small changes in heating time or sodium hydroxide concentration should have only a small effect on this precision because the phenobarbital destruction curve (Figure 1) is relatively flat at 60 mm; its general shape did not change for NaOH concentrations between 0.9 and 2 molIL.
The accuracy of the assay was acceptable, as deter- (22) . We analyzed several pentobarbital-free serum samples after alkali treatment and obtained undetectable results. This showed that the intercept was not due to a matrix effect caused by the heating step. The interference from other barbiturates followed the pattern expected from the data in the Broughton study. The other short-acting barbiturates such as secobarbital produced a large interference, whereas other long-acting barbiturates such as allobarbital and hexobarbital were effectively removed. Crossreactivity with 13 other drugs tested showed no significant interference except for phenytoin. At the upper limit of its therapeutic range, 20 mgIL, phenytoin yielded a pentobarbital equivalent of <2 mg/L in the present assay. This would not be significant at the higher pentobarbital concentrations, mgIL, but could become more significant at the lower concentrations.
In conclusion, although HPLC offers the ability to quantify several different barbiturates simultaneously, this type of equipment is not present in all clinical laboratories. Even when present, it is generally not available 24 h a day without the need to use on-call personnel. The method we present provides a convenient way to measure pentobarbital by using instrumentation readily available in most clinical laboratories. The addition of the alkaline hydrolysis step expands the application to those samples that also contain long-acting barbiturates such as phenobarbital. Other short-and intermediate-acting barbiturates cause various amounts of interference and may invalidate the assay.
